Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

132 verified discoveries match your filters.

Trial Watch: Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Bladder Cancer
Published
September 1, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 31, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Ovarian Cancer
Published
August 31, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Leukemia
Published
August 29, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Ovarian Cancer
Published
August 29, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Bladder Cancer
Published
August 28, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Leukemia
Published
August 28, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed